S&P 500   3,461.29 (+0.53%)
DOW   28,405.40 (+0.34%)
QQQ   285.91 (+0.53%)
AAPL   117.74 (+0.20%)
MSFT   214.76 (+0.05%)
FB   279.24 (+4.37%)
GOOGL   1,598.00 (+4.45%)
AMZN   3,225.00 (+0.25%)
TSLA   428.85 (+1.64%)
NVDA   546.29 (+0.09%)
BABA   311.42 (+0.52%)
CGC   20.07 (+6.30%)
GE   7.31 (-0.41%)
MU   53.32 (-0.39%)
AMD   81.09 (-0.58%)
T   26.61 (-0.56%)
F   7.78 (+0.52%)
ACB   4.88 (+7.02%)
GILD   60.20 (-0.61%)
NFLX   500.56 (-4.73%)
BA   165.84 (-0.84%)
BAC   24.21 (+0.29%)
DIS   124.70 (-0.20%)
S&P 500   3,461.29 (+0.53%)
DOW   28,405.40 (+0.34%)
QQQ   285.91 (+0.53%)
AAPL   117.74 (+0.20%)
MSFT   214.76 (+0.05%)
FB   279.24 (+4.37%)
GOOGL   1,598.00 (+4.45%)
AMZN   3,225.00 (+0.25%)
TSLA   428.85 (+1.64%)
NVDA   546.29 (+0.09%)
BABA   311.42 (+0.52%)
CGC   20.07 (+6.30%)
GE   7.31 (-0.41%)
MU   53.32 (-0.39%)
AMD   81.09 (-0.58%)
T   26.61 (-0.56%)
F   7.78 (+0.52%)
ACB   4.88 (+7.02%)
GILD   60.20 (-0.61%)
NFLX   500.56 (-4.73%)
BA   165.84 (-0.84%)
BAC   24.21 (+0.29%)
DIS   124.70 (-0.20%)
S&P 500   3,461.29 (+0.53%)
DOW   28,405.40 (+0.34%)
QQQ   285.91 (+0.53%)
AAPL   117.74 (+0.20%)
MSFT   214.76 (+0.05%)
FB   279.24 (+4.37%)
GOOGL   1,598.00 (+4.45%)
AMZN   3,225.00 (+0.25%)
TSLA   428.85 (+1.64%)
NVDA   546.29 (+0.09%)
BABA   311.42 (+0.52%)
CGC   20.07 (+6.30%)
GE   7.31 (-0.41%)
MU   53.32 (-0.39%)
AMD   81.09 (-0.58%)
T   26.61 (-0.56%)
F   7.78 (+0.52%)
ACB   4.88 (+7.02%)
GILD   60.20 (-0.61%)
NFLX   500.56 (-4.73%)
BA   165.84 (-0.84%)
BAC   24.21 (+0.29%)
DIS   124.70 (-0.20%)
S&P 500   3,461.29 (+0.53%)
DOW   28,405.40 (+0.34%)
QQQ   285.91 (+0.53%)
AAPL   117.74 (+0.20%)
MSFT   214.76 (+0.05%)
FB   279.24 (+4.37%)
GOOGL   1,598.00 (+4.45%)
AMZN   3,225.00 (+0.25%)
TSLA   428.85 (+1.64%)
NVDA   546.29 (+0.09%)
BABA   311.42 (+0.52%)
CGC   20.07 (+6.30%)
GE   7.31 (-0.41%)
MU   53.32 (-0.39%)
AMD   81.09 (-0.58%)
T   26.61 (-0.56%)
F   7.78 (+0.52%)
ACB   4.88 (+7.02%)
GILD   60.20 (-0.61%)
NFLX   500.56 (-4.73%)
BA   165.84 (-0.84%)
BAC   24.21 (+0.29%)
DIS   124.70 (-0.20%)
Log in
NASDAQ:SONN

Sonnet BioTherapeutics Stock Forecast, Price & News

$2.80
+0.04 (+1.45 %)
(As of 10/21/2020 09:33 AM ET)
Add
Compare
Today's Range
$2.78
Now: $2.80
$2.80
50-Day Range
$2.37
MA: $2.63
$2.97
52-Week Range
$2.23
Now: $2.80
$54.60
Volume35 shs
Average Volume1.80 million shs
Market Capitalization$38.20 million
P/E RatioN/A
Dividend YieldN/A
Beta0.86
SONNET BioTherapeutics, Inc. is a biotechnology company that engages in development of bi and tri functional therapies that can simulate or block immune-modulating targets to control cancer. The company uses albumin binding single chain antibody fragment (scFv) for delivery of recombinant human-cytokines (rH-cytokines) and other validated targets. SONNET BioTherapeutics, Inc. was incorporated in 2015 and is based in Princeton, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.83 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SONN
CUSIPN/A
CIKN/A
Phone609-375-2227
Employees30

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.14 million
Book Value($7.33) per share

Profitability

Net Income$-17,730,000.00

Miscellaneous

Market Cap$38.20 million
Next Earnings Date11/12/2020 (Estimated)
OptionableOptionable
$2.80
+0.04 (+1.45 %)
(As of 10/21/2020 09:33 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SONN News and Ratings via Email

Sign-up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sonnet BioTherapeutics (NASDAQ:SONN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Sonnet BioTherapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sonnet BioTherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Sonnet BioTherapeutics
.

When is Sonnet BioTherapeutics' next earnings date?

Sonnet BioTherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Sonnet BioTherapeutics
.

How were Sonnet BioTherapeutics' earnings last quarter?

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) issued its quarterly earnings results on Friday, August, 14th. The company reported ($0.44) earnings per share for the quarter. Sonnet BioTherapeutics had a negative return on equity of 779.52% and a negative net margin of 61.02%.
View Sonnet BioTherapeutics' earnings history
.

What price target have analysts set for SONN?

1 analysts have issued twelve-month price objectives for Sonnet BioTherapeutics' stock. Their forecasts range from $8.00 to $8.00. On average, they expect Sonnet BioTherapeutics' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 185.7% from the stock's current price.
View analysts' price targets for Sonnet BioTherapeutics
.

Who are some of Sonnet BioTherapeutics' key competitors?

What other stocks do shareholders of Sonnet BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sonnet BioTherapeutics investors own include Gevo (GEVO), Sorrento Therapeutics (SRNE), Boxlight (BOXL), T2 Biosystems (TTOO), Biocept (BIOC), Ibio (IBIO), Trevena (TRVN), Vaxart (VXRT), ADMA Biologics (ADMA) and Advanced Micro Devices (AMD).

Who are Sonnet BioTherapeutics' key executives?

Sonnet BioTherapeutics' management team includes the following people:
  • Dr. Pankaj Mohan, Founder, CEO & Chairman (Age 55)
  • Dr. John K. Cini Ph.D., Chief Scientific Officer & Co-Founder (Age 67)
  • Mr. Jay Cross, Chief Financial Officer (Age 49)
  • Ms. Susan Dexter, Chief Technical Officer (Age 65)
  • Dr. Terence A. Rugg, Chief Medical Officer (Age 60)

What is Sonnet BioTherapeutics' stock symbol?

Sonnet BioTherapeutics trades on the NASDAQ under the ticker symbol "SONN."

How do I buy shares of Sonnet BioTherapeutics?

Shares of SONN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sonnet BioTherapeutics' stock price today?

One share of SONN stock can currently be purchased for approximately $2.80.

How big of a company is Sonnet BioTherapeutics?

Sonnet BioTherapeutics has a market capitalization of $38.20 million and generates $30.14 million in revenue each year. Sonnet BioTherapeutics employs 30 workers across the globe.

What is Sonnet BioTherapeutics' official website?

The official website for Sonnet BioTherapeutics is www.chanticleerholdings.com.

How can I contact Sonnet BioTherapeutics?

Sonnet BioTherapeutics' mailing address is 100 OVERLOOK CENTER SUITE 102, PRINCETON NJ, 08540. The company can be reached via phone at 609-375-2227 or via email at [email protected]

This page was last updated on 10/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.